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This data article presents a dataset of mRNA levels for dopaminergic
receptors, adrenoceptors and for tyrosine hydoxylase, the rate-
limiting enzyme in the synthesis of catecholamines, in peripheral
blood mononuclear cells as well as in CD4þ T effector and regulatory
cells from subjects with clinically isolated syndromes (CIS), which is a
ﬁrst episode of neurological disturbance(s) suggestive of multiple
sclerosis. CIS subjects are divided into two groups according to their
eventual progression, after 12 months from CIS, to clinically estab-
lished multiple sclerosis. The data reported are related to the article
entitled "Dopaminergic receptors and adrenoceptors in circulating
lymphocytes as putative biomarkers for the early onset and pro-
gression of multiple sclerosis" (M. Cosentino, M. Zaffaroni, M. Legnaro,
R. Bombelli, L. Schembri, D. Baroncini, A. Bianchi, R. Clerici, M. Gui-
dotti, P. Banﬁ, G. Bono, F. Marino, 2016) [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.jneuroim.2016.07.008
(M. Cosentino).
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Dubject area Medicine
ore speciﬁc
subject areaNeurology, Immunology, Neuroimmunologyype of data Tables
ow data was
acquiredReal-time PCR, ABI PRISMs 7000 System (Applied Biosystems, Life Technologies
Corporation, USA), data statistical analysis (GraphPad Prism version 5.00 for
Windows, GraphPad Software, San Diego California USA, www.graphpad.com)ata format Analyzed
xperimental
factorsPeripheral blood mononuclear cells (PBMC) isolated by gradient centrifugation
from whole blood of subjects with clinically isolated syndromes (CIS), and cultured
for 48 h alone or with PHA 10 μg/ml. A sample of freshly isolated PBMC was used
to isolate CD4þ T effector (Teff) and regulatory (Treg) cells by means of immu-
nomagnetic sorting.xperimental
featuresReal-time PCR analysis of mRNA levels of dopaminergic receptors, adrenoceptors
and tyrosine hydroxylase mRNA levels, following total RNA extraction by Per-
fectPure™ RNA Cell & Tissue kit (5Prime, Milano, Italy), reverse transcription by a
random primer and a high-capacity cDNA RT kit (Applied Biosystems, Life Tech-
nologies Corporation, USA), and cDNA ampliﬁcation by TaqMans Universal PCR
Master Mix (Applied Biosystems), using the TaqMan Gene Expression Assay.ata source
locationVarese, Gallarate, Como (Italy)ata accessibility Data is within this articleValue of the data
 These data provide the proﬁle of expression of dopaminergic receptors, adrenoceptors and tyrosine
hydroxylase genes in circulating lymphocytes of subjects with clinically isolated syndromes (CIS).
 The data are of value for further experiments on the mechanistic role of dopaminergic and adre-
nergic pathways in circulating lymphocytes during CIS and multiple sclerosis (MS).
 The data give a basis for longitudinal, prospective clinical studies aimed at validating dopaminergic
receptors and/or adrenoceptors gene expression in lymphocytes as early markers of CIS
progressing to MS.1. Data
Enclosed are data regarding mRNA levels for dopaminergic receptors (DR), adrenoceptors (AR) and
tyrosine hydroxylase (TH), the rate-limiting enzyme in the synthesis of catecholamines, found in
peripheral blood mononuclear cells (PBMC) (Tables 1 and 2) and in CD4þ T effector (Teff) cells
(Table 3) and regulatory (Treg) cells (Table 4) from subjects with clinically isolated syndromes (CIS),
which is a ﬁrst, usually recovering, episode of neurological disturbance(s) suggestive of multiple
sclerosis (MS). Each table provides a comparison between subjects who, after 12 months from CIS, did
not progress or progressed to clinically established MS. For further information and discussion about
the interpretation and implications of DR, AR and TH mRNA levels in lymphocytes of CIS subjects,
please refer to the article [1].
Table 2
Levels of DR, AR and TH mRNA in PHA-stimulated PBMC from CIS subjects who, after 12 months from CIS, did not convert
(CISnc) or converted (CISc) to clinically established MS. Levels of mRNA are expressed as 2ΔCt107.
Gene CISnc CISc Ratio CISc/CISnc P
TH 17.349719.878 21.587723.140 1.244 0.673
DRD2 0.11170.044 0.12270.096 1.096 0.773
DRD3 212.2517102.955 227.0087146.229 1.070 0.806
DRD5 615.8917755.387 447.8907448.168 0.727 0.527
ADRA1A 0.17670.034 0.27070.116 1.540 0.052
ADRA1B 149.3477204.884 153.0147225.484 1.025 0.971
ADRA1D 212.4337152.730 199.2977132.607 0.938 0.837
ADRA2A 0.63470.484 1.43170.957 2.257 0.043
ADRA2Ba 0.03470.012 0.05170.007 1.493 0.046
ADRA2C 0.18370.169 0.20270.130 1.105 0.771
ADRB1 1.52070.794 1.30870.668 0.861 0.519
ADRB2b 6.15672.782 8.78874.242 1.428 0.141
ADRB3 0.60270.369 0.65970.295 1.095 0.698
Notes:
a ¼ levels of mRNA below detection limits in 5 CISnc and 8 CISc subjects;
b ¼data from sample of one CISc subject excluded from the analysis due to assay failure.
Table 1
Levels of DR, AR and TH mRNA in resting PBMC from CIS subjects who, after 12 months from CIS, did not convert (CISnc) or
converted (CISc) to clinically established MS. Levels of mRNA are expressed as 2ΔCt107.
Gene CISnc CISc Ratio CISc/CISnc P
TH 0.54470.469 0.58570.643 1.075 0.878
DRD2a 0.06270.010 0.08370.035 1.336 0.219
DRD3 6.28872.273 9.86874.232 1.569 0.041
DRD5 81.0737134.865 46.128742.210 0.569 0.390
ADRA1A 0.07670.034 0.08270.019 1.077 0.618
ADRA1B 0.99170.702 1.41870.806 1.431 0.232
ADRA1D 40.271710.107 43.439713.895 1.079 0.583
ADRA2A 0.07570.046 0.11670.070 1.559 0.151
ADRA2B undetected undetected n/a n/a
ADRA2C 0.05570.023 0.05370.033 0.961 0.873
ADRB1 0.55470.329 0.34270.180 0.617 0.070
ADRB2b 0.65970.582 1.18071.781 1.790 0.438
ADRB3 0.14970.084 0.18670.079 1.244 0.329
Notes:
n/a¼not applicable.
a ¼ levels of mRNA below detection limits in 3 CISnc and 3 CISc subjects;
b ¼data from sample of one CISc subject excluded from the analysis due to assay failure.
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2.1. PBMC isolation and culture
Cells were obtained from venous blood of CIS subjects enrolled at the Centre for research on
Multiple Sclerosis, Ospedale S. Antonio Abate of Gallarate (VA) (Investigator in charge: Mauro Zaf-
faroni), at the Neurology Unit of the “Ospedale di Circolo e Fondazione Macchi”, University of Insubria
- School of Medicine of Varese (Investigator in charge: Giorgio Bono), and at the Neurological
Department, Valduce Hospital, Como (Investigator in charge: Mario Guidotti). Inclusion and exclusion
criteria for selection and enrollement of CIS subjects, as well as criteria to deﬁne conversion of CIS to
Table 3
Levels of DR, AR and TH mRNA in Teff from CIS subjects who, after 12 months from CIS, did not convert (CISnc) or converted
(CISc) to clinically established MS. Levels of mRNA are expressed as 2ΔCt107.
Gene CISnc CISc Ratio CISc/CISnc P
TH 0.93270.667 1.51471.680 1.625 0.367
DRD2a 0.06170.012 0.09170.037 1.495 0.083
DRD3 71.274740.127 160.6457224.222 2.254 0.283
DRD5 38.986732.811 45.656725.700 1.171 0.617
ADRA1A 0.10470.027 0.13670.038 1.303 0.056
ADRA1B 23.090720.545 40.727730.437 1.764 0.170
ADRA1D 121.840768.792 155.881773.368 1.279 0.312
ADRA2A 0.18270.116 0.22970.134 1.263 0.421
ADRA2Ba undetected undetected n/a n/a
ADRA2C 0.05570.034 0.08570.047 1.547 0.138
ADRB1 0.89470.411 0.80170.581 0.896 0.700
ADRB2 5.47972.738 5.37974.585 0.982 0.957
ADRB3 0.22670.140 0.24370.122 1.076 0.797
Notes:
n/a¼not applicable.
a ¼ levels of mRNA below detection limits in 2 CISnc and 3 CISc subjects.
Table 4
Levels of DR, AR and TH mRNA in Treg from CIS subjects who, after 12 months from CIS, did not convert (CISnc) or converted
(CISc) to clinically established MS. Levels of mRNA are expressed as 2ΔCt107.
Gene CISnc CISc Ratio CISc/CISnc P
TH 6.23975.575 6.02975.332 0.966 0.935
DRD2a 0.09870.044 0.16270.083 1.657 0.090
DRD3b 524.5427320.649 675.0127505.025 1.287 0.470
DRD5 179.094796.190 271.145787.095 1.514 0.044
ADRA1A 0.17870.084 0.22870.096 1.277 0.260
ADRA1B 539.1187634.164 685.9477919.180 1.272 0.703
ADRA1D 273.0607162.944 431.6027273.593 1.581 0.164
ADRA2A 0.53370.401 0.70870.576 1.329 0.471
ADRA2Ba undetected undetected n/a n/a
ADRA2C 0.14770.152 0.16870.098 1.139 0.724
ADRB1 2.29972.183 1.28470.734 0.558 0.166
ADRB2 13.97479.163 15.32279.322 1.096 0.758
ADRB3 0.40270.228 0.47070.240 1.170 0.583
Notes:
n/a¼not applicable.
a ¼ levels of mRNA below detection limits in 1 CISnc and 3 CISc subjects;
b ¼data from sample of one CISc subject excluded from the analysis due to assay failure.
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the Ospedale S. Antonio Abate of Gallarate (VA), and all the participants provided a written informed
consent.
PBMC were isolated from whole blood by using Ficoll–Paque Plus density gradient centrifugation,
using standard procedures [2]. PBMC were ﬁnally cultured in RPMI 1640/10% heath-inactivated fetal
bovine serum, added with 2 mM glutamine and 100 U/ml penicillin/streptomycin, at the concentra-
tion of 1106 cells/ml, at 37 °C in a moist atmosphere of 5% CO2. Cells were cultured for 48 h, alone
or in the presence of PHA 10 μg/ml, a concentration which was previously shown to be optimal to
trigger mRNA expression of TH [3]. PBMC were ﬁnally harvested and assayed for DR, AR and TH mRNA
expression by means of real-time PCR.
Table 5
Real-Time PCR conditions.
Gene UniGene
ID
Interrogated
sequence
RefSeq/GenBank mRNA
Protein Exon
boundary
Assay
location
Amplicon
length
Efﬁciency
(%)
TH Hs.435609 NM_199292.2 NP_954986.
2
3–4 424–422 63 94.5
DRD2 Hs.73893 NM_000795.3 NP_000786.
1
2–3 524 64 100.0
DRD3 Hs.121478 NM_033663.3 NP_387512.3 3–4 809–725 73 97.6
DRD5 Hs.380681 NM_000798.4 NP_000789.
1
1–1 1092–744 88 110.2
ADRA1A Hs. 709175 NM_033302.2 NP_150645.
2
1–2 1324 112 100.0
ADRA1B Hs. 368632 NM_000679.3 NP_000670.
1
1–2 1126 61 100.0
ADRA1D Hs. 557 NM_000678.3 NP_000669.
1
1–2 1166 68 100.1
ADRA2A Hs. 249159 NM_000681.3 NP_000672.
3
1–1 1960 116 101.0
ADRA2B Hs. 247686 NM_000682.5 NP_000673.
2
1–1 823 117 100.0
ADRA2C Hs. 123022 NM_000683.3 NP_000674.
2
1–1 646 93 99.1
ADRB1 Hs. 99913 NM_000684.2 NP_000675.
1
1–1 863 79 99.0
ADRB2 Hs. 2551 NM_000024.5 NP_000015.1 1–1 778 65 100.0
ADRB3 Hs. 2549 NM_000025.2 NP_000016.1 1–2 1401 65 99.9
18S rRNA X03205.1 N.A. N.A. N.A. N.A. 187 98.8
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Immunomagnetic sorting of Treg and Teff from freshly isolated PBMC was performed by using the
Dynal CD4þCD25þ Treg Kit (Dynal, Oslo, Norway), as previously described [4]. Treg and Teff were
directly assayed for DR, AR and TH mRNA expression by means of real-time PCR.2.3. Real-time PCR
Extraction of total RNA was performed with PerfectPure™ RNA Cell & Tissue kit (5Prime, Milano,
Italy). RNA was then reverse-transcribed to cDNA using a random primer, high-capacity cDNA RT kit
(Applied Biosystems, Life Technologies Corporation, USA), and ﬁnally ampliﬁed by TaqMans Universal
PCR Master Mix (Applied Biosystems), using the TaqMan Gene Expression Assay (Table 5). Assayed of
cDNA was accomplished on an ABI PRISMs 7000 System (Applied Biosystems). Gene expression
levels were ﬁnally expressed as 2ΔCt where ΔCt¼[Ct (sample)Ct (housekeeping gene)], and nor-
malized to 18S cDNA, using the AB Prism 7000 SDS software™. Annealing temperature was 60 °C for
all the genes.2.4. Statistics
Data are reported as means7standard deviation (SD). The D'Agostino & Pearson normality test
was used to assess the distribution of values. The two-tailed Student's t test for unpaired data or the
Mann–Whitney test for continuous variables were used to assess differences between groups. Cal-
culations were performed using a commercial software (GraphPad Prism version 5.00 for Windows,
GraphPad Software, San Diego California USA, www.graphpad.com).
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